AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Treatment of Enterococcus Faecalis Bacterem

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Strasbourg, France
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Enterococcus faecalis is a germ frequently responsible for bacteremia which can be severe with 15-25% risk of mortality and 26% risk of infectious endocarditis. There is no recommendation for the treatment of "simple" Enterococcus faecalis bacteremia (meaning without infectious endocarditis at diagnosis), nor studies comparing monotherapy versus combination antibiotic therapy. Our main objective is to study the impact on mortality of bacteriostatic monotherapy and bactericidal combination antibiotic therapy in patients with Enterococcus faecalis bacteremia. We aim to also study the mortality up to three months, the failures of treatment, the modalities of treatment, the renal toxicity and the bacterial resistance.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Subject of legal age (โ‰ฅ18 years) * Having a positive blood culture result for Enterococcus faecalis identified within the microbiology laboratory of the University Hospital of Strasbourg during the period from 01 January 2017 to 31 December 2023. Exclusion Criteria: * Penicillin treatment \< 7 days * Treatment not containing a penicillin effective against enterococci among those studied: amoxicillin or piperacillin-tazobactam * Combination of penicillin with another antibiotic effective against enterococci other than cephalosporins or aminoglycosides (glycopeptides, linezolids, carbapenems, levofloxacin, moxifloxacin). * Bacteremia with one or more other pathogens within the first 7 days of bacteremia * Infective endocarditis at diagnosis and within the first 7 effective days of treatment * Resistance of Enterococcus faecalis to amoxicillin * Mortality \<72 hours after initiation of antibiotic therapy * Lack of information regarding the chosen antibiotic treatment
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy